Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
6.34
-0.43 (-6.35%)
At close: Nov 19, 2026, 4:00 PM EST
6.26
-0.08 (-1.34%)
After-hours: Nov 19, 2026, 7:30 PM EST
Atara Biotherapeutics Employees
Atara Biotherapeutics had 10 employees as of September 30, 2026. The number of employees decreased by 28 or 73.68% compared to the same quarter last year. That makes Atara Biotherapeutics the 40,202nd largest employer in the world and 6,015th in the United States.
Employees
10
Change (1Y)
-28
Growth (1Y)
-73.68%
Revenue / Employee
$396,500
Profits / Employee
-$1,461,400
Market Cap
64.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 10 | -28 | -73.68% |
| Jun 30, 2026 | 10 | -28 | -73.68% |
| Mar 31, 2026 | 13 | -76 | -85.39% |
| Dec 31, 2025 | 14 | -139 | -90.85% |
| Sep 30, 2025 | 38 | -121 | -76.10% |
| Jun 30, 2025 | 38 | -127 | -76.97% |
| Mar 31, 2025 | 89 | -84 | -48.55% |
| Dec 31, 2024 | 153 | -72 | -32.00% |
| Sep 30, 2024 | 159 | -149 | -48.38% |
| Jun 30, 2024 | 165 | -152 | -47.95% |
| Mar 31, 2024 | 173 | -157 | -47.58% |
| Dec 31, 2023 | 225 | -109 | -32.63% |
| Sep 30, 2023 | 308 | -32 | -9.41% |
| Jun 30, 2023 | 317 | -117 | -26.96% |
| Mar 31, 2023 | 330 | -240 | -42.11% |
| Dec 31, 2022 | 334 | -244 | -42.21% |
| Sep 30, 2022 | 340 | -238 | -41.18% |
| Jun 30, 2022 | 434 | -124 | -22.22% |
| Mar 31, 2022 | 570 | 90 | 18.75% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| Gossamer Bio | 162 |
| Neumora Therapeutics | 60 |
| Corbus Pharmaceuticals Holdings | 36 |
| Anavex Life Sciences | 34 |
| Cardiff Oncology | 31 |
| NeurAxis | 24 |
| PDS Biotechnology | 21 |
ATRA News
- 9 days ago - Atara Biotherapeutics files $200M mixed securities shelf - TheFly
- 9 days ago - Atara Biotherapeutics reports Q3 EPS (15c), consensus (22c) - TheFly
- 9 days ago - Atara Biotherapeutics says cash sufficient to fund operations into mid-2027 - TheFly
- 9 days ago - Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress - Business Wire
- 9 days ago - Atara Biotherapeutics Earnings release: Q3 2026 - Filings
- 9 days ago - Atara Biotherapeutics Quarterly report: Q3 2026 - Filings
- 9 days ago - Atara Biotherapeutics Registration statement: Registration filing - Filings
- 5 weeks ago - Atara partner receives acceptance by FDA of BLA resubmission for tabelecleucel - TheFly